Delivering better treatments
Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.
THE CAMURUS SHARE 127.60 SEK
-0.31% XSTO 2022-01-28 17:00
MARKET CAP: 6,920 MSEK
Transforming treatments for patients with serious and chronic diseases
Camurus' clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us.
Positive market signals for Buvidal® in Europe
FluidCrystal®- smart and versatile drug delivery
Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines.
Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden.
Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: firstname.lastname@example.org
Business Development: email@example.com Media: firstname.lastname@example.org Investor Relations: email@example.com